<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Nuvation-Bio-Inc-Ordinary-Shares-Class-A-US67080N1019">Nuvation Bio Inc - Ordinary Shares - Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/nuvation-bio-announces-positive-updated-phase-2-data-and-expansion-of-safusidenib-clinical-program-with-two-new-studies-to-explore-broad-spectrum-of-idh1-mutant-glioma-302828874.html">Nuvation Bio meldet positive aktualisierte Phase‑2-Daten und erweitert das Safusidenib‑Programm um zwei neue Studien zur Erkundung eines breiten Spektrums von IDH1‑mutierten Gliomen</a>
    </div>

      <div class="me-0 me-md-5">
        Aktualisierte Daten aus der Phase‑2‑Studie zeigen eine bestätigte objektive Ansprechrate von 52 % und eine 36‑Monate‑progressionsfreie Überlebensrate von 79 % bei fast 40 Monaten Nachbeobachtung. Neue Phase‑3‑Studie zur Bewertung von safusidenib bei neu diagnostizierten Grad‑2‑Gliompatienten außerhalb der USA. Neue Phase‑2‑Studie zur Bewertung von safusidenib bei Patienten, deren Gliom nach Beh...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Nuvation-Bio-Inc-Ordinary-Shares-Class-A-US67080N1019">Nuvation Bio Inc - Ordinary Shares - Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/nuvation-bio-inc-announces-full-exercise-of-greenshoe-option-in-287-5-million-convertible-senior-notes-offering-302818744.html">Nuvation Bio Inc. gibt vollständige Ausübung der Greenshoe-Option bei der Emission von 287,5 Mio. USD Wandelschuldverschreibungen bekannt</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK, 6. Juli 2026 /PRNewswire/ -- Nuvation Bio Inc. (&quot;Nuvation Bio&quot;) (NYSE: NUVB), ein globales Onkologie-Unternehmen, das sich der Bewältigung einiger der schwierigsten Herausforderungen in der Krebsbehandlung widmet, gab heute bekannt, dass die Konsortialbanken ihre Überzeichnungsoption (die &quot;Greenshoe-Ausübung&quot;) in vollem Umfang ausgeübt haben, um einen zusätzlichen Nennbetrag von 37,5 ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Nuvation-Bio-Inc-Ordinary-Shares-Class-A-US67080N1019">Nuvation Bio Inc - Ordinary Shares - Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/nuvation-bio-announces-marketing-authorisation-application-for-taletrectinib-for-the-treatment-of-advanced-ros1-positive-non-small-cell-lung-cancer-validated-in-the-united-kingdom-302813162.html">Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom</a>
    </div>

      <div class="me-0 me-md-5">
        FOR U.S. AUDIENCES ONLY. THIS PRESS RELEASE IS NOT FOR A U.K. AUDIENCE.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Nuvation-Bio-Inc-Ordinary-Shares-Class-A-US67080N1019">Nuvation Bio Inc - Ordinary Shares - Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/nuvation-bio-announces-pricing-of-upsized-offering-of-250-0-million-of-convertible-senior-notes-302811504.html">Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK, June 25, 2026 Nuvation Bio Inc. (&quot;Nuvation Bio&quot;) (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the pricing of its underwritten offering (the &quot;Offering&quot;) of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due in 2032 (the &quot;Notes&quot;). The aggregate principal amount of the Offerin...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Nuvation-Bio-Inc-Ordinary-Shares-Class-A-US67080N1019">Nuvation Bio Inc - Ordinary Shares - Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/nuvation-bio-announces-proposed-convertible-senior-notes-offering-302810612.html">Nuvation Bio Announces Proposed Convertible Senior Notes Offering</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK, June 25, 2026 /PRNewswire/ -- Nuvation Bio Inc. (&quot;Nuvation Bio&quot;) (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced its intent to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of Convertible Senior Notes due in 2032 (the &quot;Notes&quot;) in an underwritten offering ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Nuvation-Bio-Inc-Ordinary-Shares-Class-A-US67080N1019">Nuvation Bio Inc - Ordinary Shares - Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/nuvation-bio-to-present-at-the-jefferies-global-healthcare-conference-302783463.html">Nuvation Bio to Present at the Jefferies Global Healthcare Conference</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK, May 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in a fireside chat at the Jefferies Global ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Nuvation-Bio-Inc-Ordinary-Shares-Class-A-US67080N1019">Nuvation Bio Inc - Ordinary Shares - Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/nuvation-bio-to-present-new-quality-of-life-data-for-ibtrozi-taletrectinib-in-patients-with-ros1-positive-non-small-cell-lung-cancer-at-asco-2026-annual-meeting-302782377.html">Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting</a>
    </div>

      <div class="me-0 me-md-5">
        88% of TRUST-II patients reported improved or stable quality of life at first assessment, with the majority sustaining that benefit throughout treatment Cognitive function scores improved or remained stable throughout the course of treatment with IBTROZI IBTROZI provided rapid relief from burdensome symptoms, including cough and shortness of breath NEW YORK, May 27, 2026 /PRNewswire/ -- Nuvatio...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Nuvation-Bio-Inc-Ordinary-Shares-Class-A-US67080N1019">Nuvation Bio Inc - Ordinary Shares - Class A</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/nuvation-bio-to-collaborate-with-thermo-fisher-scientific-for-us-based-manufacturing-of-ibtrozi-for-ros1-positive-non-small-cell-lung-cancer-302771484.html">Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer</a>
    </div>

      <div class="me-0 me-md-5">
        Thermo Fisher Scientific, the world leader in serving science, will now manufacture drug product for Nuvation Bio in the United States Move by Nuvation Bio further ensures critical drug supply for patients and providers NEW YORK, May 13, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today a...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Nuvation-Bio-Inc-Ordinary-Shares-Class-A-US67080N1019/load_more?page=3">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>